Dashboard Tools Market News Investing Ideas Pricing About Us
Sign Up
Log in
Korea Pharma Co Ltd banner
K

Korea Pharma Co Ltd
KOSDAQ:032300

Watchlist Manager
Korea Pharma Co Ltd
KOSDAQ:032300
Watchlist
Price: 11 800 KRW -1.99% Market Closed
Market Cap: ₩128.7B
Write Note Create Alert Ask AI
Financials Section:
Income Statement Balance Sheet Cash Flow Statement

Cash Flow Statement

Operating Cash Flow
+
3Y
-47%
5Y
+60%
10Y
-
Investing Cash Flow
+
3Y
+63%
5Y
-694%
10Y
-
Financing Cash Flow
+
3Y
-76%
5Y
-4%
10Y
-

Cash Flow Statement
Korea Pharma Co Ltd

Rotate your device to view
Cash Flow Statement
Currency: KRW
Sep-2020 Dec-2020 Mar-2021 Jun-2021 Sep-2021 Dec-2021 Mar-2022 Jun-2022 Sep-2022 Dec-2022 Mar-2023 Jun-2023 Sep-2023 Mar-2024 Jun-2024 Sep-2024 Dec-2024 Mar-2025 Jun-2025 Sep-2025
Operating Cash Flow
Net Income
6 324
3 159
3 297
5 895
5 468
6 368
6 035
4 372
3 550
(1 119)
(1 592)
(3 030)
(2 430)
1 243
2 911
2 916
3 792
2 990
1 448
174
Depreciation & Amortization
2 790
2 221
2 320
2 857
2 392
2 377
2 272
2 344
2 464
2 380
2 565
2 659
2 715
25
12
(22)
2 797
2 904
3 012
3 100
Stock-Based Compensation
0
165
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Other Non-Cash Items
5 945
3 586
3 324
2 596
918
1 054
1 555
4 046
5 190
8 899
9 702
11 376
11 262
(1 213)
(3 735)
(4 197)
5 009
5 312
5 910
6 615
Cash Taxes Paid
1 747
1 012
373
419
(144)
(354)
97
193
200
348
819
2 252
2 245
(431)
(1 798)
(1 989)
203
487
695
929
Cash Interest Paid
709
391
351
402
257
160
142
142
163
219
238
270
302
12
2
(23)
268
239
320
411
Change in Working Capital
(11 763)
(9 840)
(9 220)
(9 592)
(4 165)
(2 607)
(1 402)
(2 685)
(1 347)
(1 881)
(4 461)
(3 671)
(6 130)
1 137
1 164
2 278
(3 552)
(4 596)
(6 578)
(4 623)
Cash from Operating Activities
3 297
N/A
(874)
N/A
(279)
+68%
1 756
N/A
4 613
+163%
7 192
+56%
8 460
+18%
8 078
-5%
9 857
+22%
8 279
-16%
6 214
-25%
7 333
+18%
5 417
-26%
1 192
-78%
352
-70%
976
+177%
8 046
+725%
6 610
-18%
3 792
-43%
5 267
+39%
Investing Cash Flow
Capital Expenditures
(3 292)
(2 644)
(2 849)
(3 512)
(3 558)
(3 450)
(3 286)
(3 756)
(3 333)
(2 752)
(3 004)
(3 020)
(2 663)
113
855
712
(3 802)
(4 023)
(3 724)
(3 622)
Other Items
796
(2 067)
(6 464)
(6 477)
(9 396)
(9 458)
(5 061)
(54 958)
(49 609)
(49 124)
(41 325)
(2 541)
1 573
(9 691)
(567)
70
(8 534)
(4 975)
(16 097)
(16 198)
Cash from Investing Activities
(2 495)
N/A
(4 711)
-89%
(9 313)
-98%
(9 989)
-7%
(12 954)
-30%
(12 908)
+0%
(8 347)
+35%
(58 714)
-603%
(52 942)
+10%
(51 875)
+2%
(44 329)
+15%
(5 560)
+87%
(1 089)
+80%
(9 578)
-779%
288
N/A
783
+172%
(12 335)
N/A
(8 998)
+27%
(19 822)
-120%
(19 819)
+0%
Financing Cash Flow
Net Issuance of Common Stock
16 606
16 606
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Net Issuance of Debt
(4 993)
(4 161)
(3 585)
(4 863)
(4 390)
45 908
45 920
45 926
45 918
(4 018)
(3 055)
(2 041)
(2 026)
(1 930)
(5 645)
(12 819)
(14 751)
(11 790)
4 016
11 278
Cash Paid for Dividends
(439)
(439)
0
0
(545)
(545)
(1 091)
(1 091)
(545)
(545)
(545)
(545)
(545)
0
0
0
(545)
(545)
(545)
(545)
Other
0
0
0
(545)
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Cash from Financing Activities
11 174
N/A
12 005
+7%
13 021
+8%
11 197
-14%
(4 936)
N/A
45 363
N/A
44 829
-1%
45 380
+1%
45 373
0%
(4 563)
N/A
(3 601)
+21%
(2 586)
+28%
(2 571)
+1%
(1 930)
+25%
(5 645)
-193%
(12 819)
-127%
(15 296)
-19%
(12 335)
+19%
3 471
N/A
10 732
+209%
Change in Cash
Effect of Foreign Exchange Rates
14
1
(6)
(6)
26
29
19
63
147
9
24
(29)
(102)
18
24
(49)
70
33
(52)
85
Net Change in Cash
11 989
N/A
6 422
-46%
3 424
-47%
2 958
-14%
(13 250)
N/A
39 675
N/A
44 962
+13%
(5 192)
N/A
2 434
N/A
(48 150)
N/A
(41 692)
+13%
(842)
+98%
1 654
N/A
(10 296)
N/A
(4 981)
+52%
(11 109)
-123%
(19 516)
-76%
(14 691)
+25%
(12 611)
+14%
(3 734)
+70%
Free Cash Flow
Free Cash Flow
6
N/A
(3 518)
N/A
(3 128)
+11%
(1 756)
+44%
1 055
N/A
3 742
+255%
5 174
+38%
4 322
-16%
6 524
+51%
5 527
-15%
3 210
-42%
4 313
+34%
2 755
-36%
1 306
-53%
1 207
-8%
1 688
+40%
4 245
+151%
2 587
-39%
67
-97%
1 646
+2 339%

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Follow us
Join more than 315,900+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.